Zobrazeno 1 - 4
of 4
pro vyhledávání: '"EG Arshanskaya"'
Autor:
E. I. Emelina, OYu Vinogradova, Igor G. Nikitin, G. E. Gendlin, Immunology, Samory Mashela str., Moscow, Russian Federation, Anastasiya Bykova, IE Lazarev, EYu Chelysheva, EG Arshanskaya, Galina Gusarova, L M Makeeva, Anna G. Turkina
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 13, Iss 1, Pp 104-111 (2019)
Aim. To analyze adverse cardiovascular events in chronic myeloid leukemia (CML) patients who received various tyrosine kinase inhibitors (TKI). Materials & Methods. The trial included 97 CML patients with nilotinib, dasatinib or imatinib indications.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7fc3302de67febb6b4b1068d2217458
https://doi.org/10.21320/2500-2139-2020-13-1-104-111
https://doi.org/10.21320/2500-2139-2020-13-1-104-111
Autor:
AV Shubina, OYu Vinogradova, E. I. Emelina, GE Gendlin, MA Panteleev, MM Pankrashkina, E A Nikitin, Vadim V. Ptushkin, S A Lugovskaya, EA Dmitrieva, EE Markova, EG Arshanskaya, VV Glazunova, T N Obukhova, NK Khuazheva, Pochtar' Me, Valentina Ivanova, NG Novitskaya, YuB Kochkareva, LA Mukha, IE Lazarev, E. V. Naumova, SA Chernysh
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 10, Iss 3, Pp 271-281 (2017)
Background & Aims. This paper presents the results of the observational study of ibrutinib in patients with chronic lymphocytic leukemia (CLL), conducted in SP Botkin Municipal Clinical Hospital. The main objective was the analysis of complications o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61c195876623d9edb1dbb58aad28254f
https://doi.org/10.21320/2500-2139-2017-10-3-271-281
https://doi.org/10.21320/2500-2139-2017-10-3-271-281
Autor:
Vadim V. Ptushkin, N.E. Tkachenko, EG Arshanskaya, MM Pankrashkina, M V Chernikov, O.Yu. Vinogradova
Publikováno v:
Терапевтический архив, Vol 90, Iss 7, Pp 70-76 (2018)
Objective: To analyze the long-term efficacy and safety of ATR in adult patients with primary resistant ITP in real-world clinical practice. Materials and methods.The article contains long-term results analysis of ATR application under real clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::401324dcf61db0f836e80e71cc74ed68
https://pubmed.ncbi.nlm.nih.gov/30701925
https://pubmed.ncbi.nlm.nih.gov/30701925
Publikováno v:
Europe PubMed Central
Between 1997 and 2008, 97 adolescents and young adults with a median age 18.9 years (range, 15.0-33.6) with all stages Hodgkin's lymphoma (HL) were treated by a pediatric protocol DAL-HD-90m. The 12-year event-free survival and overall survival was 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3f1a051b537df8d9a6c9e613936e76de
http://europepmc.org/abstract/med/26995990
http://europepmc.org/abstract/med/26995990
